Catalent has appointed Karen Flynn as president of biologics and chief commercial officer. Ms. Flynn has also joined the company’s executive leadership team and will report to Alessandro Maselli, Catalent’s president and chief operating officer. Ms. Flynn takes on the role previously held by Mr. Barry Littlejohns, who will be retiring.   Ms. Flynn assumes global responsibility for Catalent’s biologics business, including the several investments and expansions currently taking place, which includ...